Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinson's disease

Mov Disord. 2018 Apr;33(4):583-591. doi: 10.1002/mds.27328. Epub 2018 Feb 28.

Abstract

Background and hypothesis: To date, there are no chemical analytes, including biochemical indices of oxidative stress, metabolites of α-synuclein protein, and differential protein expression patterns on proteomic profiling, for use in clinics as a diagnostic biomarker of idiopathic PD.

Objectives: Heme oxygenase-1 has been implicated in the pathogenesis of PD. The objective of this study is to ascertain whether salivary heme oxygenase-1 may serve as a biomarker for early idiopathic PD.

Methods: Fifty-eight PD patients and 59 non-neurological disease controls were recruited. Levels of heme oxygenase-1 expression were assayed using enzyme-linked immunosorbent assay and western blot analysis of whole, unstimulated saliva. Analyses were adjusted by sex, l-dopa exposure, and relevant comorbidities.

Results: We documented: (1) the presence of 32-kDa heme oxygenase-1 protein in human saliva; (2) significantly higher mean heme oxygenase-1 protein concentrations in saliva of PD patients relative to control values; (3) no variability in salivary heme oxygenase-1 levels with sex, age, l-dopa equivalence, or comorbidities; and (4) significantly higher mean salivary heme oxygenase-1 concentrations in patients with H & Y stage 1 PD (early) than control subjects and stage 2 and stage 3 PD patients. The area under the receiver operating characteristic curve that separated controls from PD H & Y stage 1 was 76% (95% confidence interval: 63-90).

Conclusions: Salivary heme oxygenase-1 concentrations may provide a useful, noninvasive, and relatively inexpensive biomarker of early idiopathic PD. © 2018 International Parkinson and Movement Disorder Society.

Keywords: Parkinson's disease; aging; biomarker; heme oxygenase-1; saliva.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antiparkinson Agents / therapeutic use
  • Biomarkers / metabolism*
  • Female
  • Heme Oxygenase-1 / metabolism*
  • Humans
  • Levodopa / therapeutic use
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy
  • Parkinson Disease / enzymology*
  • ROC Curve
  • Retrospective Studies
  • Saliva / drug effects
  • Saliva / enzymology*
  • Sex Factors

Substances

  • Antiparkinson Agents
  • Biomarkers
  • Levodopa
  • Heme Oxygenase-1

Grants and funding